Overview

Vaccine Therapy With or Without Imiquimod in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma

Status:
Completed

Trial end date:
2006-07-28

Target enrollment:

Participant gender:

Summary

RATIONALE: Vaccines made from peptides may help the body build an effective immune response to kill tumor cells. Biological therapies, such as imiquimod, may stimulate the immune system in different ways and stop tumor cells from growing. Giving vaccine therapy together with imiquimod after surgery may help the body kill any remaining tumor cells. PURPOSE: This randomized phase I trial is studying the side effects and best way to give vaccine therapy with or without imiquimod in treating patients who have undergone surgery for stage II, stage III, or stage IV melanoma.

Phase:

Phase 1

Details

Lead Sponsor:

Craig L Slingluff, Jr

Collaborator:

National Cancer Institute (NCI)

Treatments:

Dimethyl Sulfoxide
Freund's Adjuvant
Imiquimod
Sargramostim
Vaccines